Ortho Biotech Oncology Research & Development Data to Be Presented at the 51st Annual Meeting of the American Society of Hematology (ASH)

Note: This release corresponds to ASH abstracts 109, 131, 2312, 3859 and 3875

BEERSE, Belgium, December 4 - Ortho Biotech Oncology Research & Development, a division of Janssen
Pharmaceutica N.V., today announced that data related to several of its
oncology compounds will be presented at the 51st Annual Meeting of the
American Society of Hematology (ASH) in New Orleans, Louisiana, from December
5th to December 8th, 2009.

"As an organization, we are very committed to meeting the needs of
patients with hematologic disorders and malignancies, and to advancing
science in this area," said Peter Ho, Head of Development for Oncology, Ortho
Biotech Oncology Research & Development. "In this exciting time in clinical
research, we are pleased that these data are being presented at ASH."

These following clinical studies, selected for oral or poster
presentation, were sponsored either by Ortho Biotech Oncology Research &
Development or its research partners, including: Johnson & Johnson
Pharmaceutical Research & Development, LLC, Centocor Ortho Biotech Inc.,
Centocor R&D, Inc. and Janssen-Cilag GmbH. (Note that these studies are
grouped by compound and listed in date order within each section.):

    VELCADE(R) (bortezomib)

    - VELCADE, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction
      for Previously Untreated Multiple Myeloma (German DSMM XIa Trial)
      (Abstract 131)

    Oral and Poster Abstracts
    Oral Session: Myeloma - Therapy, excluding Transplantation: Combination
    Therapy for Newly Diagnosed Multiple Myeloma
    Sunday, December 6, 2009, 5:30 PM CST, Hall F (Ernest N. Morial
    Convention Center)
    Authors: H. Einsele, P. Liebisch, C. Langer, et al.

    - Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus
      Cyclophosphamide as Induction Therapy in Previously Untreated Multiple
      Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
      (Abstract 2312)

    Oral and Poster Abstracts
    Poster Session: Clinical Results - Autologous Transplantation Poster II
    Sunday, December 6, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial
    Convention Center), Poster Board II-289
    Authors: H. Ludwig, L. Viterbo, R. Greil, et al.

    - Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a
      Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial
      in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and
      Extensive Subsequent Therapy Use (Abstract 3859)

    Oral and Poster Abstracts
    Poster Session: Myeloma - Therapy, excluding Transplantation Poster III
    Monday, December 7, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial
    Convention Center), Poster Board III-795
    Authors: MV. Mateos, P. G. Richardson, R. Schlag, et al.

    - Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral
      Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus
      Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma
      (Abstract 3875)

    Oral and Poster Abstracts
    Poster Session: Myeloma - Therapy, excluding Transplantation Poster III
    Monday, December 7, 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial
    Convention Center), Poster Board III-811
    Authors: D. S. Ricci, R. Favis, Y. Sun, et al.

    VELCADE(R) / DOXIL(R) (doxorubicin HCl liposome injection)

    - Polymorphisms in the Multiple Drug Resistance Protein 1 and in
      P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients
      with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib
      and Pegylated Liposomal Doxorubicin (Abstract 109)

    Oral and Poster Abstracts
    Oral Session: Molecular Pharmacology, Drug Resistance I
    Sunday, December 6, 2009, 4:30 PM CST, R06-R09 (Ernest N. Morial
    Convention Center)
    Authors: G. Buda, D. Ricci, N. Cohen, et al.

About VELCADE(R)

VELCADE is the first proteasome inhibitor to receive worldwide regulatory
approval for the treatment of multiple myeloma (MM). In 2005, VELCADE was
approved in the European Union for MM after relapse and has now received
approval from the European Commission in combination with melphalan and
prednisone for the treatment of patients with previously untreated MM who are
not eligible for high-dose chemotherapy with bone marrow transplant.

Notes for Editors:

About VELCADE(R)

VELCADE is a medicine used to treat the blood based cancer known as
multiple myeloma. It contains an active substance called bortezomib and is
the first in a new class of medicines known as proteasome inhibitors.
Proteasomes are present in all cells and play an important role in
controlling cell function, growth and also how cells interact with the other
cells around them. VELCADE reversibly interrupts the normal working of cell
proteasomes causing myeloma cancer cells to stop growing and die.(1)

For further information on VELCADE see the EU Summary of Product
Characteristics (SmPC):
emc.medicines.org.uk/document.aspx?documentId=17109

About Janssen-Cilag

Janssen-Cilag is one of the world's leading research-based pharmaceutical
companies, with operations throughout the world. In the UK, Janssen-Cilag
Limited employs more than 500 people.

The company is committed to discovering and delivering innovative
medicines for diseases of high unmet medical need and has introduced a range
of treatments that make an important difference to the lives of patients with
serious health conditions.

Key areas of activity include; psychiatry; neurology; oncology;
immunology; HIV; antibiotics; pain management; fungal diseases/dermatology;
gastroenterology and women's health.

Key products include Risperdal(R) (schizophrenia, bipolar disorder),
Risperdal(R) Consta(R) (schizophrenia), Concerta(R) XL (ADHD), Velcade(R)
(oncology), Prezista(R) & Intelence(R) (HIV), Stelara(R) (psoriasis),
Topamax(R) (epilepsy, migraine), Doribax(R) (antibiotics), Daktarin(R)
(anti-fungal), Sporanox (anti-fungal), Durogesic(R) DTrans(R) (pain
management), Pariet(R) (gastroenterology), Cilest(R) and Evorel(R) (women's
health).

Medicines developed by Janssen-Cilag are used to treat around 1,500
million patients worldwide every year.

Janssen-Cilag is part of the Johnson & Johnson family of companies, which
comprises around 250 operating companies throughout the world and employs
approximately 120,000 people in 57 countries, 6,000 of them in the UK.
Johnson & Johnson is the world's most comprehensive and broadly based
manufacturer of health care products and related services.

More information can be found at www.janssen-cilag.co.uk

Reference: EU Summary of Product Characteristics (SmPC):
emc.medicines.org.uk/document.aspx?documentId=17109

Jennifer Tear, Communications EMEA, +32-146-026-38